MedPath

Bausch & Lomb Incorporated

🇺🇸United States
Ownership
-
Established
1992-10-08
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis

Phase 3
Completed
Conditions
Allergic Conjunctivitis
Interventions
Drug: Placebo
First Posted Date
2007-01-17
Last Posted Date
2013-03-14
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
90
Registration Number
NCT00423007
Locations
🇺🇸

ISTA Pharmaceuticals, Inc., Irvine, California, United States

Pediatric Zylet Safety and Efficacy Study

Phase 4
Completed
Conditions
Chalazion
Hordeolum
Interventions
Drug: vehicle
First Posted Date
2007-01-11
Last Posted Date
2011-10-07
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
108
Registration Number
NCT00420628
Locations
🇺🇸

Pediatric Ophthalmology of Erie, Erie, Pennsylvania, United States

Systemic Pharmacokinetics of BOL-303224-A

Phase 1
Completed
Conditions
Conjunctivitis, Bacterial
Interventions
First Posted Date
2006-12-05
Last Posted Date
2011-12-09
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
24
Registration Number
NCT00407589
Locations
🇺🇸

Cornerstone Eyecare, High point, North Carolina, United States

Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants

Phase 2
Completed
Conditions
Noninfectious Posterior Uveitis
Interventions
First Posted Date
2006-12-04
Last Posted Date
2011-12-08
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
278
Registration Number
NCT00407082
Locations
🇺🇸

Duke Eye Center, Durham, North Carolina, United States

A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis

Phase 2
Withdrawn
Conditions
Allergic Conjunctivitis
First Posted Date
2006-09-13
Last Posted Date
2015-02-20
Lead Sponsor
Bausch & Lomb Incorporated
Registration Number
NCT00375596

Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome

Phase 2
Completed
Conditions
Dry Eye Syndromes
Interventions
Drug: Placebo
First Posted Date
2006-09-01
Last Posted Date
2013-03-15
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
162
Registration Number
NCT00370747

A Study to Investigate the Safety and Effectiveness of Aspheric Laser Refractive Surgery Treatments for Myopia

Not Applicable
Completed
Conditions
Myopia
Astigmatism
First Posted Date
2006-08-17
Last Posted Date
2011-12-08
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
127
Registration Number
NCT00365677

A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.

Phase 3
Completed
Conditions
Acute Bacterial Conjunctivitis
Interventions
Drug: Vehicle
First Posted Date
2006-07-04
Last Posted Date
2015-03-24
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
957
Registration Number
NCT00347932

Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment

Phase 2
Terminated
Conditions
Vitreoretinal Traction Syndrome
Interventions
Drug: Vehicle
First Posted Date
2006-07-04
Last Posted Date
2019-06-21
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
29
Registration Number
NCT00348439
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)

Not Applicable
Completed
Conditions
Healthy
First Posted Date
2006-07-04
Last Posted Date
2014-01-17
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
76
Registration Number
NCT00347594
Locations
🇺🇸

Bausch & Lomb, Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy